BR112017020826A2 - compostos, composição farmacêutica e kit - Google Patents
compostos, composição farmacêutica e kitInfo
- Publication number
- BR112017020826A2 BR112017020826A2 BR112017020826-1A BR112017020826A BR112017020826A2 BR 112017020826 A2 BR112017020826 A2 BR 112017020826A2 BR 112017020826 A BR112017020826 A BR 112017020826A BR 112017020826 A2 BR112017020826 A2 BR 112017020826A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- kit
- pharmaceutical composition
- relates
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000003781 beta lactamase inhibitor Substances 0.000 abstract 1
- -1 beta-lactam compounds Chemical class 0.000 abstract 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305479.6A EP3075734A1 (en) | 2015-03-31 | 2015-03-31 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP15305479.6 | 2015-03-31 | ||
| EP16305059 | 2016-01-22 | ||
| EP16305059.4 | 2016-01-22 | ||
| PCT/EP2016/056845 WO2016156346A1 (en) | 2015-03-31 | 2016-03-30 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020826A2 true BR112017020826A2 (pt) | 2018-07-03 |
Family
ID=55642466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020826-1A BR112017020826A2 (pt) | 2015-03-31 | 2016-03-30 | compostos, composição farmacêutica e kit |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10570131B2 (https=) |
| EP (1) | EP3277685B1 (https=) |
| JP (1) | JP2018510190A (https=) |
| KR (1) | KR20170131687A (https=) |
| CN (1) | CN107438610A (https=) |
| AU (1) | AU2016239207A1 (https=) |
| BR (1) | BR112017020826A2 (https=) |
| CA (1) | CA2980109A1 (https=) |
| CL (1) | CL2017002449A1 (https=) |
| HK (1) | HK1244791A1 (https=) |
| MX (1) | MX2017012539A (https=) |
| RU (1) | RU2715058C2 (https=) |
| TW (1) | TW201639853A (https=) |
| WO (2) | WO2016156346A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3300736B1 (en) * | 2016-09-30 | 2021-05-05 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| EP3357924A1 (en) | 2017-02-06 | 2018-08-08 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| EP3833665B1 (en) | 2018-08-09 | 2023-07-19 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009091856A2 (en) * | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
| MX348974B (es) * | 2011-08-27 | 2017-07-04 | Wockhardt Ltd | Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. |
| CA2845108C (en) * | 2011-08-30 | 2015-06-16 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections |
| AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| HUE046893T2 (hu) | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
| US9271446B2 (en) * | 2012-06-28 | 2016-03-01 | Forage Innovations B.V. | Self-aligning apparatus and methods for gathering bales |
| RU2614418C2 (ru) * | 2012-08-25 | 2017-03-28 | Вокхардт Лимитед | Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций |
| EP2953626A1 (en) * | 2013-02-06 | 2015-12-16 | Astrazeneca AB | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| US10786458B2 (en) | 2015-03-31 | 2020-09-29 | Laboratorios Bago S.A. | Procedure for preparing enteric-coated pellets containing a proton pump inhibitor and multi-particle pharmaceutical compositions containing them |
| EP3075733A1 (en) | 2015-03-31 | 2016-10-05 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| EP3075734A1 (en) * | 2015-03-31 | 2016-10-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| MA41850A (fr) | 2015-03-31 | 2018-02-06 | Takeda Pharmaceuticals Co | Nouvelles utilisations pharmaceutiques |
-
2016
- 2016-03-30 US US15/563,483 patent/US10570131B2/en active Active
- 2016-03-30 TW TW105110155A patent/TW201639853A/zh unknown
- 2016-03-30 RU RU2017133745A patent/RU2715058C2/ru active
- 2016-03-30 WO PCT/EP2016/056845 patent/WO2016156346A1/en not_active Ceased
- 2016-03-30 AU AU2016239207A patent/AU2016239207A1/en not_active Abandoned
- 2016-03-30 CN CN201680020427.5A patent/CN107438610A/zh active Pending
- 2016-03-30 KR KR1020177031506A patent/KR20170131687A/ko not_active Withdrawn
- 2016-03-30 MX MX2017012539A patent/MX2017012539A/es unknown
- 2016-03-30 BR BR112017020826-1A patent/BR112017020826A2/pt not_active Application Discontinuation
- 2016-03-30 CA CA2980109A patent/CA2980109A1/en not_active Abandoned
- 2016-03-30 JP JP2017551331A patent/JP2018510190A/ja active Pending
- 2016-03-30 EP EP16712866.9A patent/EP3277685B1/en active Active
- 2016-03-30 HK HK18104010.8A patent/HK1244791A1/zh unknown
- 2016-03-30 WO PCT/EP2016/056842 patent/WO2016156344A1/en not_active Ceased
-
2017
- 2017-09-28 CL CL2017002449A patent/CL2017002449A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017012539A (es) | 2018-09-28 |
| EP3277685B1 (en) | 2021-01-13 |
| CL2017002449A1 (es) | 2018-04-20 |
| HK1244791A1 (zh) | 2018-08-17 |
| RU2017133745A (ru) | 2019-03-28 |
| CN107438610A (zh) | 2017-12-05 |
| TW201639853A (zh) | 2016-11-16 |
| KR20170131687A (ko) | 2017-11-29 |
| WO2016156344A1 (en) | 2016-10-06 |
| JP2018510190A (ja) | 2018-04-12 |
| WO2016156346A1 (en) | 2016-10-06 |
| US10570131B2 (en) | 2020-02-25 |
| CA2980109A1 (en) | 2016-10-06 |
| RU2017133745A3 (https=) | 2019-09-09 |
| EP3277685A1 (en) | 2018-02-07 |
| US20180086760A1 (en) | 2018-03-29 |
| AU2016239207A1 (en) | 2017-10-12 |
| RU2715058C2 (ru) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017020935A2 (pt) | ?compostos, composição farmacêutica e conjunto? | |
| BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
| BR112017020796A2 (pt) | compostos, composição farmacêutica e kit | |
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| BR112018067930A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
| BR112016016854A2 (pt) | Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| BR112016018604A2 (pt) | Benzimidazol-2-aminas como inibidores de midh1 | |
| EA033311B1 (ru) | Производные бензоксаборола в качестве антибактериальных средств | |
| BR112015017241A8 (pt) | composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit | |
| BR112014004515A2 (pt) | "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende" | |
| BR112014026058A2 (pt) | composições para tratamento tópico de infecções microbianas | |
| BR112017023359A2 (pt) | ?compostos, composições farmacêuticas e kits? | |
| BR112017004153A2 (pt) | métodos para tratamento de infecções por protozoários | |
| BR112015029367A8 (pt) | combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| BR112017011980A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção bacteriana. | |
| BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
| BR112016022722B8 (pt) | Composto, composição farmacêutica que o comprende e uso do mesmo | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| HK1243951A1 (zh) | 抗微生物组合和其在治疗微生物感染中的用途 | |
| BR112016022749A2 (pt) | compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2 | |
| BR112017020826A2 (pt) | compostos, composição farmacêutica e kit | |
| BR112015000616A2 (pt) | tratamento da esclerose múltipla com combinação de laquinimode e fampridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |